WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
Tweet
Share
E-mailGet Alerts AKBA Hot Sheet
Price: $0.92 +2.22%
Rating Summary:
13 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Rating Summary:
13 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Join SI Premium – FREE
WestPark Capital initiates coverage on Akebia Therapeutics (NASDAQ: AKBA) with a Buy rating and a price target of $4.50.
For an analyst ratings summary and ratings history on Akebia Therapeutics click here. For more ratings news on Akebia Therapeutics click here.
Shares of Akebia Therapeutics closed at $0.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rothschild Redburn Starts Minimax Group Inc (100:HK) at Buy
- National Bank Financial Starts Banyan Gold Corp (BYN:CN) at Outperform
- Rothschild Redburn Starts Core Scientific Inc. (CORZ) at Neutral
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
